July 29 (Reuters) - Inventiva SA IVAA.PA :
* REPROTED ON WEDENSDAY H1 REVENUE EUR 0.2 MLN VS EUR 0.1
MLN YR
AGO
* CASH AND CASH EQUIVALENTS AT EUR 93.6 MLN AS OF JUNE 30,
2021 VS
EUR 107.8 MLN AS OF MARCH 31, 2021 AND EUR 113.02 MLN AS OF DEC
31, 2020
* INVENTIVA’S CASH RUNWAY WILL ALLOW TO FUND ITS OPERATING
ACTIVITIES THROUGH THE THIRD QUARTER OF 2022
* OVER H1, CO RECORDED POSITIVE EXCHANGE RATE EFFECT ON CASH
AND
CASH EQUIVALENT OF EUR 1.2 MLN
* EXPECTS TO RECEIVE ANOTHER MILESTONE PAYMENT UPON THE
INITIATION
BY ABBVIE ABBV.N OF PHASE IIB CLINICAL TRIAL WITH CEDIROGANT
BEFORE END-2021
Source text for Eikon: ID:nGNE46tncq
Further company coverage: IVAA.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))